19.96%SPY 79.52 
5.39%XLF 9.68 3.09%
Digg
Del.icio.us
Newsvine 
Facebook
Stumbleupon
BRIDGEWATER, N.J. - Enzon Pharmaceuticals Inc. said Tuesday the newest version of its cancer drug Oncaspar has received orphan drug status in the European Union.
| ENZN | 4.64 |  0.34 |
Oncaspar-IV is a treatment for acute lymphoblastic leukemia, the most common type of cancer in children. The Commission of the European Communities awarded the drug orphan medicinal product status, which will block rival versions of the drug from the market for 10 years if regulators approve Oncaspar-IV for sale.
Oncaspar is designed to kill cancer cells by starving them of an essential amino acid.
In morning trading, Enzon shares slipped 18 cents, or 2.3 percent, to $7.52.
China's bid to establish its own next generation mobile phone technology standard got a boost from the world's biggest cell phone maker...
U.S stocks fell on Wednesday as investors grew concerned that a bailout loan package for ailing automakers would fail to be approved by U.S. lawm...
An international meeting has set new guidelines aimed at preventing tobacco companies from trying to influence national and global health policy....
Split Big Profits! You Find it & We Fund it! Co-Own Or Cash Out! Get Free Info Kit Now!
Baldwin Linguas:
Translations Interpreting Localization:
English French Portuguese Spanish
Get your next web design project done with our los angeles web design team - Best web design with great price.
Partners   
|
© 2008 The Ibtimes Company. All Rights Reserved. Terms of service | Privacy Policy | Advertising | About Us | Contact Us | Archives
EMAIL
PRINT
RSS
SHARE
